The share value of USA-based Capricor Therapeutics (Nasdaq: CAPR) was worth 62% less at Friday’s close than it was a day earlier after the announcement of a disastrous trial analysis on its lead candidate, CAP-1002.
Capricor, which was trading at just $1.16 by Friday evening, plans to reduce the scope of its operations, including the size of its workforce, in order to now focus its financial resources primarily on its Duchenne muscular dystrophy (DMD) program.
A pre-specified administrative interim analysis was performed on six-month follow-up data from the ALLSTAR Trial, an ongoing randomized, double-blind, placebo-controlled, 142-patient Phase II clinical trial of CAP-1002 (allogeneic cardiosphere-derived cells) in adults who have experienced a large heart attack with residual cardiac dysfunction.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze